BRIEF-J&J Expects The U.S. FDA To Close Inspection Of Emergent Bayview Facility This Week - Conf Call

Johnson & Johnson: * J&J CFO EXPECTS SECOND QUARTER 2021 SALES SHOULD COMPARE HIGHLY FAVORABLY TO Q2 2020 IN MEDICAL DEVICES

* J&J EXECUTIVE SAYS CO STANDS BY POSITIVE RISK/BENEFIT PROFILE OF COVID-19 VACCINE AS PANDEMIC CONTINUES TO RAGE AROUND THE WORLD * J&J EXECUTIVE SAYS LOOKING FORWARD TO OUTCOME OF EMA COMMITTEE MEETING, AND STANDS READY TO RESUME VACCINATIONS IN EUROPE

* J&J EXECUTIVE SAYS REMAIN COMMITTED TO DELIVER 200 MILLION DOSES TO EU, NORWAY AND ICELAND * J&J EXEC SAYS COMMITTED TO DELIVERING 100 MILLION DOSES OF ITS COVID-19 VACCINE TO U.S.- CONF CALL

* J&J EXEC SAYS TO WORK WITH EU COUNTRIES TO RESUME VACCINATIONS IN ALL JANSSEN COVID-19 VACCINE CLINICAL TRIALS IN EUROPE - CONF CALL * J&J EXEC SAYS STILL AIMS TO SECURE U.S. AUTHORIZATION FOR COVID-19 VACCINE DRUG SUBSTANCE MADE AT EMERGENT'S BAYVIEW FACILITY - CONF CALL

* J&J EXEC EXPECTS THE U.S. FDA TO CLOSE INSPECTION OF EMERGENT BAYVIEW FACILITY THIS WEEK - CONF CALL Further company coverage: